SCHEMBL6846935

SCHEMBL6846935

CNC(=O)c1ccccc1Oc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.63
L3MBTL1 Q9Y468 4/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
NPSR1 Q6W5P4 1/20 0.61
CTNNB1 P35222 2/20 0.61
ALDH1A1 P00352 4/20 0.58
GAA P10253 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
MAPK8 P45983 1/20 0.58
HPGD P15428 1/20 0.58
HTT P42858 1/20 0.58
ATM Q13315 1/20 0.58
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.55
HSD17B10 Q99714 1/20 0.55
KDM4E B2RXH2 1/20 0.55
KAT2B Q92831 1/20 0.51
BAZ2B Q9UIF8 1/20 0.51
TCF4 P15884 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21556908 0.88 SCN8A (0.56) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL19361291 0.88 MMP13 (0.58) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL18401369 0.87 RAB9A (0.54) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL27565872 0.87 RAB9A (0.57) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL2646539 0.85 KAT2B (0.57) RAB9AGAAHPGDTSHRMAPK1
SCHEMBL21334373 0.84 RAB9A (0.55) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL974852 0.84 CTNNB1 (0.62) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL21556888 0.83 MEN1 (0.49) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL6689471 0.83 ALDH1A1 (0.64) RAB9AL3MBTL1MEN1KMT2ANPSR1
SCHEMBL12376719 0.83 NPSR1 (0.60) RAB9AL3MBTL1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295136-A1 Analogs of Nitrofuran Antibiotics to Combat Resistance ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2023-09-21 US disclosed
CN-109096221-A The method that the oxidation of catalytic molecular oxygen generates benzoisothiazolinone class compound in water phase 郑州大学 2018-12-28 CN disclosed
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 US disclosed
CN-101130526-B Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK AS 2013-07-10 CN disclosed
EP-2113502-A1 Hydrazyde type compounds and the use thereof in pharmaceutical compositions for the treatment of cardiovascular diseases Clinigenetics (FR) 2009-11-04 EP disclosed
CN-101130526-A Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK AS (DK) 2008-02-27 CN disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed
CN-1678311-A Arylcarbonyl derivatives useful as therapeutic agents NOVO NORDISK AS (DK) 2005-10-05 CN disclosed
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
EP-1268484-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed
WO-2001068652-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed
US-4208205-A Herbicidal benzamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC RAB9A 2056/4885L3MBTL1 3393/4885MEN1 3149/4885
US-20230295136-A1 Analogs of Nitrofuran Antibiotics to Combat Resistance ATF4, ATF1, FBL RAB9A 3191/4885L3MBTL1 159/4885MEN1 4351/4885
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 RAB9A 1533/4885L3MBTL1 3041/4885MEN1 1139/4885
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS KDM5A, KDM5C, KDM5B RAB9A 3251/4885L3MBTL1 1933/4885MEN1 3356/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 RAB9A 1533/4885L3MBTL1 3041/4885MEN1 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.